| 摘要 |
Use of galectin-2 or of a nucleic acid coding for galectin-2 or of its complementary strand, or of a nucleic acid hybridizing to such coding nuclei c acid or its complementary strand, for the manufacture of a medicament for th e treatment or prevention of a patient having a disease with impaired apoptosi s of T-cells, macrophages and/or antigen-presenting cells, or for the manufacture of a medicament for the treatment or prevention of organ rejecti on in a patient having undergone organ transplantation, in particular solid org an transplantation. |
